Literature DB >> 7624001

Lipoprotein glomerulopathy: first case in a white European.

A Meyrier1, F Dairou, P Callard, B Mougenot.   

Abstract

Since 1988, 11 cases of a new entity, 'Lipoprotein glomerulopathy' (LG), were described in Japan. Some of these reports suggested that this glomerular lipid storage is due to excess apo E associated with heterozygous E2/3 apo E isoform. We report the first case of LG in a white European with no such lipid abnormalities. Proteinuria was discovered in 1967 when he was 42. Blood pressure and renal function were normal. Family history was negative. Renal biopsy disclosed lesions which were only understood at the time of the Japanese publications. They were composed of endocapillary glomerular deposits. Staining for lipids disclosed capillary loop obstruction with lipid droplets. Electron microscopy showed confluent droplets of various sizes obstructing capillary loops. Proteinuria progressively increased. In 1974 repeat renal biopsy showed the same lipid deposits, now associated with focal-segmental glomerulosclerosis (FSGS). Several serum lipoprotein and apolipoprotein studies ruled out any specific lipid derangement. This suggested a local glomerular disorder, presumably affecting the glomerular endocapillary disposal of lipids. A third biopsy showed progressive glomerular destruction by FSGS with persistence of the lipid droplets. Renal insufficiency progressed and haemodialysis was started in 1992. This observation suggests that LG is a local glomerular, not a general lipid disorder and indicates that this disease is not restricted to Asian patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7624001     DOI: 10.1093/ndt/10.4.546

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  8 in total

1.  Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice.

Authors:  Hagai Tavori; Daping Fan; Ilaria Giunzioni; Lin Zhu; MacRae F Linton; Agnes B Fogo; Sergio Fazio
Journal:  J Lipid Res       Date:  2014-09-02       Impact factor: 5.922

2.  Lipoprotein Glomerulopathy, First Case Report from Canada.

Authors:  Julie Anne Ting; Susanna A McRae; Daniel Schwartz; Sean J Barbour; Maziar Riazy
Journal:  Int J Nephrol Renovasc Dis       Date:  2022-06-21

Review 3.  An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.

Authors:  Meng-Shi Li; Yang Li; Yang Liu; Xu-Jie Zhou; Hong Zhang
Journal:  Front Med (Lausanne)       Date:  2022-05-06

Review 4.  Adaptive and maladaptive roles of lipid droplets in health and disease.

Authors:  Jeffrey D Pressly; Margaret Z Gurumani; Javier T Varona Santos; Alessia Fornoni; Sandra Merscher; Hassan Al-Ali
Journal:  Am J Physiol Cell Physiol       Date:  2022-02-02       Impact factor: 4.249

5.  Lipoprotein Glomerulopathy in a Hispanic Female: A Case Report and Literature Review.

Authors:  Nasma K Majeed; Jeanette McLaughlin; Miguel Gonzalez
Journal:  Can J Kidney Health Dis       Date:  2019-06-27

6.  A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports.

Authors:  Runxiu Wang; Chengbo Zhao; Wen Chen; Zhiping Liu; Fuhua Xie
Journal:  J Med Case Rep       Date:  2022-02-23

7.  Lipoprotein glomerulopathy associated with a mutation in apolipoprotein e.

Authors:  Riccardo Magistroni; Marco Bertolotti; Luciana Furci; Rita Adriana Fano; Marco Leonelli; Livia Pisciotta; Elisa Pellegrini; Laura Calabresi; Stefano Bertolini; Sebastiano Calandra
Journal:  Clin Med Insights Case Rep       Date:  2013-12-05

8.  Lipoprotein glomerulopathy resulting from compound heterogeneous mutations of APOE gene: A case report.

Authors:  Yunsi Li; Jin Chen; Yurong Zou; Wei Wang; Guisen Li
Journal:  Medicine (Baltimore)       Date:  2022-02-04       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.